BeiGene
BGNE
#984
Rank
NZ$34.83 B
Marketcap
$312.42
Share price
1.55%
Change (1 day)
6.33%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of September 2024 : NZ$10.17 Billion

According to BeiGene 's latest financial reports the company's total assets are NZ$10.17 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31NZ$9.17 B-8.64%
2022-12-31NZ$10.04 B-19.59%
2021-12-31NZ$12.49 B60.99%
2020-12-31NZ$7.76 B224.24%
2019-12-31NZ$2.39 B-28.62%
2018-12-31NZ$3.35 B127.61%
2017-12-31NZ$1.47 B151.51%
2016-12-31NZ$0.58 B243.4%
2015-12-31NZ$0.17 B149.29%
2014-12-31NZ$68.43 M376.68%
2013-12-31NZ$14.35 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
NZ$31.7 M-99.69%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$3.93 B-61.31%๐Ÿ‡บ๐Ÿ‡ธ USA